Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.
Nature Genetics
Kar, Siddhartha P SP; Quiros, Pedro M PM; Gu, Muxin M; Jiang, Tao T; Mitchell, Jonathan J; Langdon, Ryan R; Iyer, Vivek V; Barcena, Clea C; Vijayabaskar, M S MS; Fabre, Margarete A MA; Carter, Paul P; Petrovski, Slavé S; Burgess, Stephen S; Vassiliou, George S GS
Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.
The Journal Of Pathology
Cyrta, Joanna J; Prandi, Davide D; Arora, Arshi A; Hovelson, Daniel H DH; Sboner, Andrea A; Rodriguez, Antonio A; Fedrizzi, Tarcisio T; Beltran, Himisha H; Robinson, Dan R DR; Gopalan, Anuradha A; True, Lawrence L; Nelson, Peter S PS; Robinson, Brian D BD; Mosquera, Juan Miguel JM; Tomlins, Scott A SA; Shen, Ronglai R; Demichelis, Francesca F; Rubin, Mark A MA
KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
Plos One
Rudd, Meghan L ML; Hansen, Nancy F NF; Zhang, Xiaolu X; Urick, Mary Ellen ME; Zhang, Suiyuan S; Merino, Maria J MJ; , ; Mullikin, James C JC; Brody, Lawrence C LC; Bell, Daphne W DW
KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas.
Plos One
Rudd, Meghan L ML; Hansen, Nancy F NF; Zhang, Xiaolu X; Urick, Mary Ellen ME; Zhang, Suiyuan S; Merino, Maria J MJ; , ; Mullikin, James C JC; Brody, Lawrence C LC; Bell, Daphne W DW
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Frontiers In Endocrinology
Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C
Genomic and transcriptomic landscape of conjunctival melanoma.
Plos Genetics
Cisarova, Katarina K; Folcher, Marc M; El Zaoui, Ikram I; Pescini-Gobert, Rosanna R; Peter, Virginie G VG; Royer-Bertrand, Beryl B; Zografos, Leonidas L; Schalenbourg, Ann A; Nicolas, Michael M; Rimoldi, Donata D; Leyvraz, Serge S; Riggi, Nicolò N; Moulin, Alexandre P AP; Rivolta, Carlo C
Integrated molecular drivers coordinate biological and clinical states in melanoma.
Nature Genetics
Conway, Jake R JR; Dietlein, Felix F; Taylor-Weiner, Amaro A; AlDubayan, Saud S; Vokes, Natalie N; Keenan, Tanya T; Reardon, Brendan B; He, Meng Xiao MX; Margolis, Claire A CA; Weirather, Jason L JL; Haq, Rizwan R; Schilling, Bastian B; Stephen Hodi, F F; Schadendorf, Dirk D; Liu, David D; Van Allen, Eliezer M EM
Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).
Clinical Sarcoma Research
Heinrich, Michael C MC; Patterson, Janice J; Beadling, Carol C; Wang, Yuexiang Y; Debiec-Rychter, Maria M; Dewaele, Barbara B; Corless, Christopher L CL; Duensing, Anette A; Raut, Chandrajit P CP; Rubin, Brian B; Ordog, Tamas T; van de Rijn, Matt M; Call, Jerry J; Mühlenberg, Thomas T; Fletcher, Jonathan A JA; Bauer, Sebastian S
Downregulation of SPTAN1 is related to MLH1 deficiency and metastasis in colorectal cancer.
Plos One
Ackermann, Anne A; Schrecker, Christopher C; Bon, Dimitra D; Friedrichs, Nicolaus N; Bankov, Katrin K; Wild, Peter P; Plotz, Guido G; Zeuzem, Stefan S; Herrmann, Eva E; Hansmann, Martin-Leo ML; Brieger, Angela A
Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma.
Npj Systems Biology And Applications
Del Mistro, Greta G; Lucarelli, Philippe P; Müller, Ines I; De Landtsheer, Sébastien S; Zinoveva, Anna A; Hutt, Meike M; Siegemund, Martin M; Kontermann, Roland E RE; Beissert, Stefan S; Sauter, Thomas T; Kulms, Dagmar D
Novel BRAF alteration in desmoplastic infantile ganglioglioma with response to targeted therapy.
Acta Neuropathologica Communications
Blessing, Melissa M MM; Blackburn, Patrick R PR; Balcom, Jessica R JR; Krishnan, Chandra C; Harrod, Virginia L VL; Zimmermann, Michael T MT; Barr Fritcher, Emily G EG; Zysk, Christopher D CD; Jackson, Rory A RA; Nair, Asha A AA; Jenkins, Robert B RB; Halling, Kevin C KC; Kipp, Benjamin R BR; Ida, Cristiane M CM
Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach.
Oncotarget
Del Carmen, Sofía S; Sayagués, José María JM; Bengoechea, Oscar O; Anduaga, María Fernanda MF; Alcazar, Jose Antonio JA; Gervas, Ruth R; García, Jacinto J; Orfao, Alberto A; Bellvis, Luis Muñoz LM; Sarasquete, María Eugenia ME; Del Mar Abad, María M
Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
International Journal Of Oncology
Fratangelo, Federica F; Camerlingo, Rosa R; Carriero, Maria Vincenza MV; Pirozzi, Giuseppe G; Palmieri, Giuseppe G; Gentilcore, Giusy G; Ragone, Concetta C; Minopoli, Michele M; Ascierto, Paolo Antonio PA; Motti, Maria Letizia ML
Sadeghi, Rochelle Shirin RS; Kulej, Katarzyna K; Kathayat, Rahul Singh RS; Garcia, Benjamin A BA; Dickinson, Bryan C BC; Brady, Donita C DC; Witze, Eric S ES
Genetic alterations in main candidate genes during melanoma progression.
Oncotarget
Sini, Maria Cristina MC; Doneddu, Valentina V; Paliogiannis, Panagiotis P; Casula, Milena M; Colombino, Maria M; Manca, Antonella A; Botti, Gerardo G; Ascierto, Paolo A PA; Lissia, Amelia A; Cossu, Antonio A; Palmieri, Giuseppe G
Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.
American Journal Of Clinical Dermatology
Kuske, Marvin M; Rauschenberg, Ricarda R; Garzarolli, Marlene M; Meredyth-Stewart, Michelle M; Beissert, Stefan S; Troost, Esther G C EGC; Glitza, Oliva Isabella Claudia OIC; Meier, Friedegund F
Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
Melanoma Research
Bisschop, Cornelis C; Ter Elst, Arja A; Bosman, Lisette J LJ; Platteel, Inge I; Jalving, Mathilde M; van den Berg, Anke A; Diepstra, Arjan A; van Hemel, Bettien B; Diercks, Gilles F H GFH; Hospers, Geke A P GAP; Schuuring, Ed E
Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma.
Plos One
Gaiser, Maria Rita MR; Skorokhod, Alexander A; Gransheier, Diana D; Weide, Benjamin B; Koch, Winfried W; Schif, Birgit B; Enk, Alexander A; Garbe, Claus C; Bauer, Jürgen J
Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation.
Oncotarget
Caliò, Anna A; Eble, John N JN; Hes, Ondrej O; Martignoni, Guido G; Harari, Saul E SE; Williamson, Sean R SR; Brunelli, Matteo M; Osunkoya, Adeboye O AO; Wang, Lisha L; Comperat, Eva E; Lopez-Beltran, Antonio A; Wang, Mingsheng M; Zhang, Shaobo S; Curless, Kendra L KL; Post, Kristin M KM; Chang, Hsim-Yee HY; Luchini, Claudio C; Baldrige, Lee Ann LA; MacLennan, Gregory T GT; Montironi, Rodolfo R; Grignon, David J DJ; Cheng, Liang L
Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.
The Journal Of Investigative Dermatology
Thomas, Nancy E NE; Edmiston, Sharon N SN; Kanetsky, Peter A PA; Busam, Klaus J KJ; Kricker, Anne A; Armstrong, Bruce K BK; Cust, Anne E AE; Anton-Culver, Hoda H; Gruber, Stephen B SB; Luo, Li L; Orlow, Irene I; Reiner, Anne S AS; Gallagher, Richard P RP; Zanetti, Roberto R; Rosso, Stefano S; Sacchetto, Lidia L; Dwyer, Terence T; Parrish, Eloise A EA; Hao, Honglin H; Gibbs, David C DC; Frank, Jill S JS; Ollila, David W DW; Begg, Colin B CB; Berwick, Marianne M; Conway, Kathleen K; ,
Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma.
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Nature
Yao, Zhan Z; Yaeger, Rona R; Rodrik-Outmezguine, Vanessa S VS; Tao, Anthony A; Torres, Neilawattie M NM; Chang, Matthew T MT; Drosten, Matthias M; Zhao, Huiyong H; Cecchi, Fabiola F; Hembrough, Todd T; Michels, Judith J; Baumert, Hervé H; Miles, Linde L; Campbell, Naomi M NM; de Stanchina, Elisa E; Solit, David B DB; Barbacid, Mariano M; Taylor, Barry S BS; Rosen, Neal N
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Nature Communications
Chen, Fengju F; Zhang, Yiqun Y; Bossé, Dominick D; Lalani, Aly-Khan A AA; Hakimi, A Ari AA; Hsieh, James J JJ; Choueiri, Toni K TK; Gibbons, Don L DL; Ittmann, Michael M; Creighton, Chad J CJ
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.
British Journal Of Cancer
Alvi, Muhammad A MA; Loughrey, Maurice B MB; Dunne, Philip P; McQuaid, Stephen S; Turkington, Richard R; Fuchs, Marc-Aurel MA; McGready, Claire C; Bingham, Victoria V; Pang, Brendan B; Moore, Wendy W; Maxwell, Perry P; Lawler, Mark M; James, Jacqueline A JA; Murray, Graeme I GI; Wilson, Richard H RH; Salto-Tellez, Manuel M
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
The Lancet. Oncology
Davies, Michael A MA; Saiag, Philippe P; Robert, Caroline C; Grob, Jean-Jacques JJ; Flaherty, Keith T KT; Arance, Ana A; Chiarion-Sileni, Vanna V; Thomas, Luc L; Lesimple, Thierry T; Mortier, Laurent L; Moschos, Stergios J SJ; Hogg, David D; Márquez-Rodas, Iván I; Del Vecchio, Michele M; Lebbé, Céleste C; Meyer, Nicolas N; Zhang, Ying Y; Huang, Yingjie Y; Mookerjee, Bijoyesh B; Long, Georgina V GV
HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.
The Journal Of Biological Chemistry
Zhao, Liang L; Fan, Jun J; Xia, Siyuan S; Pan, Yaozhu Y; Liu, Shuangping S; Qian, Guoqing G; Qian, Zhiyu Z; Kang, Hee-Bum HB; Arbiser, Jack L JL; Pollack, Brian P BP; Kudchadkar, Ragini R RR; Lawson, David H DH; Rossi, Michael M; Abdel-Wahab, Omar O; Merghoub, Taha T; Khoury, Hanna J HJ; Khuri, Fadlo R FR; Boise, Lawrence H LH; Lonial, Sagar S; Chen, Fangping F; Chen, Jing J; Lin, Ruiting R
Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition.
Scientific Reports
Hardeman, Keisha N KN; Peng, Chengwei C; Paudel, Bishal B BB; Meyer, Christian T CT; Luong, Thong T; Tyson, Darren R DR; Young, Jamey D JD; Quaranta, Vito V; Fessel, Joshua P JP
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.
Nature Communications
Schütte, Moritz M; Risch, Thomas T; Abdavi-Azar, Nilofar N; Boehnke, Karsten K; Schumacher, Dirk D; Keil, Marlen M; Yildiriman, Reha R; Jandrasits, Christine C; Borodina, Tatiana T; Amstislavskiy, Vyacheslav V; Worth, Catherine L CL; Schweiger, Caroline C; Liebs, Sandra S; Lange, Martin M; Warnatz, Hans-Jörg HJ; Butcher, Lee M LM; Barrett, James E JE; Sultan, Marc M; Wierling, Christoph C; Golob-Schwarzl, Nicole N; Lax, Sigurd S; Uranitsch, Stefan S; Becker, Michael M; Welte, Yvonne Y; Regan, Joseph Lewis JL; Silvestrov, Maxine M; Kehler, Inge I; Fusi, Alberto A; Kessler, Thomas T; Herwig, Ralf R; Landegren, Ulf U; Wienke, Dirk D; Nilsson, Mats M; Velasco, Juan A JA; Garin-Chesa, Pilar P; Reinhard, Christoph C; Beck, Stephan S; Schäfer, Reinhold R; Regenbrecht, Christian R A CR; Henderson, David D; Lange, Bodo B; Haybaeck, Johannes J; Keilholz, Ulrich U; Hoffmann, Jens J; Lehrach, Hans H; Yaspo, Marie-Laure ML
Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.
Genome Research
Brammeld, Jonathan S JS; Petljak, Mia M; Martincorena, Inigo I; Williams, Steven P SP; Alonso, Luz Garcia LG; Dalmases, Alba A; Bellosillo, Beatriz B; Robles-Espinoza, Carla Daniela CD; Price, Stacey S; Barthorpe, Syd S; Tarpey, Patrick P; Alifrangis, Constantine C; Bignell, Graham G; Vidal, Joana J; Young, Jamie J; Stebbings, Lucy L; Beal, Kathryn K; Stratton, Michael R MR; Saez-Rodriguez, Julio J; Garnett, Mathew M; Montagut, Clara C; Iorio, Francesco F; McDermott, Ultan U
A variant by any name: quantifying annotation discordance across tools and clinical databases.
Genome Medicine
Yen, Jennifer L JL; Garcia, Sarah S; Montana, Aldrin A; Harris, Jason J; Chervitz, Stephen S; Morra, Massimo M; West, John J; Chen, Richard R; Church, Deanna M DM
Publication Date: 2017-01-26
Variant appearance in text: BRAF: 1799_1800delTGinsAT; V600D
MicroRNAs in melanoma development and resistance to target therapy.
Oncotarget
Fattore, Luigi L; Costantini, Susan S; Malpicci, Debora D; Ruggiero, Ciro Francesco CF; Ascierto, Paolo Antonio PA; Croce, Carlo M CM; Mancini, Rita R; Ciliberto, Gennaro G
Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.
Oncotarget
Mukherjee, Nabanita N; Almeida, Adam A; Partyka, Katie A KA; Lu, Yan Y; Schwan, Josianna V JV; Lambert, Karoline K; Rogers, Madison M; Robinson, William A WA; Robinson, Steven E SE; Applegate, Allison J AJ; Amato, Carol M CM; Luo, Yuchun Y; Fujita, Mayumi M; Norris, David A DA; Shellman, Yiqun G YG
The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.
Molecular Cancer Therapeutics
Delgado-Goni, Teresa T; Miniotis, Maria Falck MF; Wantuch, Slawomir S; Parkes, Harold G HG; Marais, Richard R; Workman, Paul P; Leach, Martin O MO; Beloueche-Babari, Mounia M
miR-579-3p controls melanoma progression and resistance to target therapy.
Proceedings Of The National Academy Of Sciences Of The United States Of America
Fattore, Luigi L; Mancini, Rita R; Acunzo, Mario M; Romano, Giulia G; Laganà, Alessandro A; Pisanu, Maria Elena ME; Malpicci, Debora D; Madonna, Gabriele G; Mallardo, Domenico D; Capone, Marilena M; Fulciniti, Franco F; Mazzucchelli, Luca L; Botti, Gerardo G; Croce, Carlo M CM; Ascierto, Paolo Antonio PA; Ciliberto, Gennaro G
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine.
Genome Medicine
Garofalo, Andrea A; Sholl, Lynette L; Reardon, Brendan B; Taylor-Weiner, Amaro A; Amin-Mansour, Ali A; Miao, Diana D; Liu, David D; Oliver, Nelly N; MacConaill, Laura L; Ducar, Matthew M; Rojas-Rudilla, Vanesa V; Giannakis, Marios M; Ghazani, Arezou A; Gray, Stacy S; Janne, Pasi P; Garber, Judy J; Joffe, Steve S; Lindeman, Neal N; Wagle, Nikhil N; Garraway, Levi A LA; Van Allen, Eliezer M EM
RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma.
Oncotarget
Goedert, Lucas L; Pereira, Cristiano G CG; Roszik, Jason J; Plaça, Jessica R JR; Cardoso, Cibele C; Chen, Guo G; Deng, Wanleng W; Yennu-Nanda, Vashisht Gopal VG; Silva, Wilson A WA; Davies, Michael A MA; Espreafico, Enilza M EM
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
Journal Of Translational Medicine
Schreuer, Max M; Meersseman, Geert G; Van Den Herrewegen, Sari S; Jansen, Yanina Y; Chevolet, Ines I; Bott, Ambre A; Wilgenhof, Sofie S; Seremet, Teofila T; Jacobs, Bart B; Buyl, Ronald R; Maertens, Geert G; Neyns, Bart B
Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.
Oncotarget
Eriksson, Johanna J; Le Joncour, Vadim V; Nummela, Pirjo P; Jahkola, Tiina T; Virolainen, Susanna S; Laakkonen, Pirjo P; Saksela, Olli O; Hölttä, Erkki E
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
Journal Of The National Cancer Institute
Sabbatino, Francesco F; Wang, Yangyang Y; Scognamiglio, Giosuè G; Favoino, Elvira E; Feldman, Steven A SA; Villani, Vincenzo V; Flaherty, Keith T KT; Nota, Sjoerd S; Giannarelli, Diana D; Simeone, Ester E; Anniciello, Anna M AM; Palmieri, Giuseppe G; Pepe, Stefano S; Botti, Gerardo G; Ascierto, Paolo A PA; Ferrone, Cristina R CR; Ferrone, Soldano S